<p>(<b>A</b>) Treatment of OSC19 cells with GSPs decreases the basal levels of NF-κB/p65 and IKKα while inhibiting the degradation of IκBα. After treatment of cells for 48 h with various concentrations of GSPs the cells were harvested, cytosolic and nuclear fractions were prepared and these were subjected to western blot analysis. Representative blots are shown from three independent experiments with identical observations. (<b>B</b>) The activity of NF-κB/p65 in the nuclear fraction of cells after treatment with and without GSPs was measured using an NF-κB/p65-specific activity assay kit, n = 3. Activity of NF-κB/p65 is expressed in terms of percent of the control (non-GSPs-treated) group. Significant decrease versus control: <sup>¶</sup><...
<p>The effects of (A) gefitinib and (B) erlotinib (1–10 μM) on cell proliferation of A549 cells were...
<p>(<b>A</b>) 435s/M14 cells, transfected with STAT3 siRNA, were drug treated (8 h), and nuclear fra...
<p><b>A–B</b>, Protein lysates from HCC827 (A) and HCC4006 (B) cells treated with DMSO (vehicle) or ...
<p>(<b>A</b>) Treatment of A375 cells with GSPs decreases the basal levels of NF-κB/p65 and IKKα whi...
<p>(<b>A</b>), Treatment of SCC1 and OSC19 cells with GSPs decreases the overexpression of EGFR and ...
<p>(<b>A</b>) Treatment of OSC19 cells with GSPs for 48 h enhanced the levels of epithelial biomarke...
<p>(<b>A</b>) GSPs inhibit the activation of ERK1/2 in OSC19 cells in a dose-dependent manner. OSC19...
<p>(A) A2780/T cells were incubated with 40 μM of GSP for indicated times. The lysates were subjecte...
<p>(<b>A</b>) OSC19 cells were treated with the indicated concentrations of GSPs for 48 h and the ef...
<p>(<b>A</b>) OSC19 cells were treated with the indicated concentrations of erlotinib, a small molec...
<p>(A) A2780/T cells were incubated with 0∼40 μM of GSP for 6h then stimulated with or without 1 μg/...
<p>(A) Western blot analysis to see the nuclear and cytosolic expression of NF-κB in MDA-MB 231 cell...
<p>Western blot analysis of NFκB members p65 and IκBα in non-differentiated (St-T1, first line; KdS1...
<p>A549 cells were treated with gefitinib (10 μM), erlotinib (10 μM) or tunicamycin (2.5 μg/mL) for ...
<p>(A) The effect of NF-κB inhibition on the induction of A20, TNF-α and IL-1β. THP-1 cells, pre-tre...
<p>The effects of (A) gefitinib and (B) erlotinib (1–10 μM) on cell proliferation of A549 cells were...
<p>(<b>A</b>) 435s/M14 cells, transfected with STAT3 siRNA, were drug treated (8 h), and nuclear fra...
<p><b>A–B</b>, Protein lysates from HCC827 (A) and HCC4006 (B) cells treated with DMSO (vehicle) or ...
<p>(<b>A</b>) Treatment of A375 cells with GSPs decreases the basal levels of NF-κB/p65 and IKKα whi...
<p>(<b>A</b>), Treatment of SCC1 and OSC19 cells with GSPs decreases the overexpression of EGFR and ...
<p>(<b>A</b>) Treatment of OSC19 cells with GSPs for 48 h enhanced the levels of epithelial biomarke...
<p>(<b>A</b>) GSPs inhibit the activation of ERK1/2 in OSC19 cells in a dose-dependent manner. OSC19...
<p>(A) A2780/T cells were incubated with 40 μM of GSP for indicated times. The lysates were subjecte...
<p>(<b>A</b>) OSC19 cells were treated with the indicated concentrations of GSPs for 48 h and the ef...
<p>(<b>A</b>) OSC19 cells were treated with the indicated concentrations of erlotinib, a small molec...
<p>(A) A2780/T cells were incubated with 0∼40 μM of GSP for 6h then stimulated with or without 1 μg/...
<p>(A) Western blot analysis to see the nuclear and cytosolic expression of NF-κB in MDA-MB 231 cell...
<p>Western blot analysis of NFκB members p65 and IκBα in non-differentiated (St-T1, first line; KdS1...
<p>A549 cells were treated with gefitinib (10 μM), erlotinib (10 μM) or tunicamycin (2.5 μg/mL) for ...
<p>(A) The effect of NF-κB inhibition on the induction of A20, TNF-α and IL-1β. THP-1 cells, pre-tre...
<p>The effects of (A) gefitinib and (B) erlotinib (1–10 μM) on cell proliferation of A549 cells were...
<p>(<b>A</b>) 435s/M14 cells, transfected with STAT3 siRNA, were drug treated (8 h), and nuclear fra...
<p><b>A–B</b>, Protein lysates from HCC827 (A) and HCC4006 (B) cells treated with DMSO (vehicle) or ...